Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
Abstract Aims Cardiac transthyretin amyloidosis (ATTR‐CM) is a progressive and fatal condition. Prognosis can be determined at diagnosis according to the National Amyloidosis Centre (NAC) transthyretin amyloidosis (ATTR) stage. We sought to examine how NAC ATTR stage changes during follow‐up and whe...
Main Authors: | Steven Law, Aviva Petrie, Liza Chacko, Oliver C. Cohen, Sriram Ravichandran, Janet A. Gilbertson, Dorota Rowczenio, Ashutosh Wechalekar, Ana Martinez‐Naharro, Helen J. Lachmann, Carol J. Whelan, David F. Hutt, Philip N. Hawkins, Marianna Fontana, Julian D. Gillmore |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-12-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.12989 |
Similar Items
-
Hereditary transthyretin amyloidosis
by: T. A. Adyan, et al.
Published: (2020-01-01) -
The role of non-coding genetic variants on transthyretin gene transcription in transthyretin amyloidosis
by: Boldbaatar, Batbold
Published: (2021) -
Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis
by: Bokyung Kim, et al.
Published: (2021-03-01) -
A Clinical Case of the Hereditary Transthyretin Amyloidosis
by: E. V. Reznik, et al.
Published: (2021-05-01) -
Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure
by: Gabriela Molina O, et al.
Published: (2014-11-01)